New Grant Program Releases RFA to Support Research Projects with Commercial Potential

November 17, 2014

Investigators from the University of Minnesota and the Mayo Clinic have a new opportunity to advance their research, thanks to the launch of a collaborative grant program that is now accepting applications.

CTSI and the Mayo Clinic Center for Clinical and Translational Science (CCaTS) established the Translational Product Development Fund (TPDF) program in conjunction with the Minnesota Partnership for Biotechnology and Medical Genomics (MNP).

The TPDF program supports the advancement of projects that have the potential to be commercialized, such as projects that aim to form a start-up company or create a license agreement with an established commercial entity. Ultimately, the program aims to impact the lives of Minnesotans by translating research discoveries into new therapies and treatment approaches for patients.

All full-time University of Minnesota faculty (all campuses) and Mayo Clinic Associate Consultant to Consultant investigators from the Rochester campus are invited to apply. 

The program offers two levels of possible funding:

  • Tier 1: Awards up to $50,000 in total direct costs to support projects that aim to establish scientific and technical merit, feasibility, and commercial potential.
  • Tier 2: Awards up to $200,000 to advance projects past the feasibility assessment as described in Tier 1, and toward the creation of a commercial entity or licensing agreement; applications for this tier require approval from program administration.

In addition, awardees will receive a customized project development team (PDT) to help advance projects along the translational development pathway.

Learn more about this grant program and view other current CTSI funding opportunities.

Tags